Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24: 2137-50. 10.1200/JCO.2005.05.2308.
Article
PubMed
Google Scholar
Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.
Article
PubMed
Google Scholar
Rivera F, Vega-Villegas ME, López-Brea MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007, 33: 315-24. 10.1016/j.ctrv.2007.01.004.
Article
PubMed
CAS
Google Scholar
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993, 72: 37-41. 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P.
Article
PubMed
CAS
Google Scholar
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995, 71: 587-91.
Article
PubMed
PubMed Central
Google Scholar
Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997, 8: 163-8. 10.1023/A:1008243606668.
Article
PubMed
CAS
Google Scholar
Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study -FFCD 9803. J Clin Oncol. 2004, 22: 4319-28. 10.1200/JCO.2004.01.140.
Article
PubMed
Google Scholar
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V-325 Study Group. J Clin Oncol. 2006, 24: 4991-7. 10.1200/JCO.2006.06.8429.
Article
PubMed
CAS
Google Scholar
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007, 18: 510-7. 10.1093/annonc/mdl459.
Article
PubMed
CAS
Google Scholar
Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). ASCO Meeting Abstracts. 2007, 4513-
Google Scholar
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008, 358: 36-46. 10.1056/NEJMoa073149.
Article
PubMed
CAS
Google Scholar
Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK: A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer. 2008, 98: 316-22. 10.1038/sj.bjc.6604186.
Article
PubMed
CAS
PubMed Central
Google Scholar
Thuss-Patience P, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Gebauer B, Schumacher G, Reichardt P: Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Inter-nistische Onkologie (AIO). ECCO15-ESMO34. 2009, Abstract O-6504
Google Scholar
Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F, Yan J, Zhan ZY, Feng M: A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs. 2009, 20: 281-6. 10.1097/CAD.0b013e328324bbc1.
Article
PubMed
CAS
Google Scholar
Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008, 8: 148-10.1186/1471-2407-8-148.
Article
PubMed
PubMed Central
Google Scholar
Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY: Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol. 2008, 31: 259-63. 10.1097/COC.0b013e31815d43ee.
Article
PubMed
Google Scholar
Lawley PD, Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res. 1996, 355: 13-40.
Article
PubMed
Google Scholar
Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P: Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998, 54: 770-7.
PubMed
CAS
Google Scholar
Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 2000, 58: 920-7.
PubMed
CAS
Google Scholar
Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33: 9-23. 10.1016/j.ctrv.2006.09.006.
Article
PubMed
CAS
PubMed Central
Google Scholar
Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ: Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry. 1996, 35: 10004-13. 10.1021/bi960453+.
Article
PubMed
CAS
Google Scholar
Levine RL, Miller H, Grollman A, Ohashi E, Ohmori H, Masutani C, Hanaoka F, Moriya M: Translesion DNA synthesis catalyzed by human pol eta and pol kappa across 1, N6-ethenodeoxyadenosine. J Biol Chem. 2001, 276: 18717-21. 10.1074/jbc.M102158200.
Article
PubMed
CAS
Google Scholar
Vaisman A, Masutani C, Hanaoka F, Chaney SG: Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry. 2000, 39: 4575-80. 10.1021/bi000130k.
Article
PubMed
CAS
Google Scholar
Matsuda T, Bebenek K, Masutani C, Hanaoka F, Kunkel TA: Low fidelity DNA synthesis by human DNA polymerase eta. Nature. 2000, 404: 1011-3. 10.1038/35010014.
Article
PubMed
CAS
Google Scholar
Albertella MR, Green CM, Lehmann AR, O'Connor MJ: A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res. 2005, 65: 9799-806. 10.1158/0008-5472.CAN-05-1095.
Article
PubMed
CAS
Google Scholar
Ceppi P, Novello S, Cambieri A, Longo M, Monica V, Lo Iacono M, Giaj-Levra M, Saviozzi S, Volante M, Papotti M, Scagliotti G: Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2009, 15: 1039-45. 10.1158/1078-0432.CCR-08-1227.
Article
PubMed
CAS
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-47. 10.1016/j.ejca.2008.10.026.
Article
PubMed
CAS
Google Scholar
Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2006, 5: 39-47.
Article
PubMed
CAS
Google Scholar
Masutani C, Kusumoto R, Yamada A, Dohmae N, Yokoi M, Yuasa M, Araki M, Iwai S, Takio K, Hanaoka F: The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 1999, 399: 700-4. 10.1038/21447.
Article
PubMed
CAS
Google Scholar
Masutani C, Araki M, Yamada A, Kusumoto R, Nogimori T, Maekawa T, Iwai S, Hanaoka F: Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity. EMBO J. 1999, 18: 3491-501. 10.1093/emboj/18.12.3491.
Article
PubMed
CAS
PubMed Central
Google Scholar
Cleaver JE, Arutyunyan RM, Sarkisian T, Kaufmann WK, Greene AE, Coriell L: Similar defects in DNA repair and replication in the pigmented xerodermoid and the xeroderma pigmentosum variants. Carcinogenesis. 1980, 1: 647-55. 10.1093/carcin/1.8.647.
Article
PubMed
CAS
Google Scholar
Wang YC, Maher VM, Mitchell DL, McCormick JJ: Evidence from mutation spectra that the UV hypermutability of xeroderma pigmentosum variant cells reflects abnormal, error-prone replication on a template containing photoproducts. Mol Cell Biol. 1993, 13: 4276-83.
Article
PubMed
CAS
PubMed Central
Google Scholar
Lehmann AR: Replication of damaged DNA in mammalian cells: New solutions to an old problem. Mutat Res. 2002, 509: 23-34.
Article
PubMed
CAS
Google Scholar